MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate – Business Wire (press release)
Business Wire (press release) |
MeiraGTx Receives EMA PRIME Designation for Achromatopsia Gene Therapy Candidate
Business Wire (press release) LONDON & NEW YORK–(BUSINESS WIRE)–MeiraGTx, a London and New York based gene therapy company, announced today the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to MeiraGTx’s gene therapy product candidate A002 for … |
SelectScience |
Editorial Article: 7 Steps to Better Gene Editing and CRISPR technology – Special Feature
SelectScience In this editorial feature, we bring you the latest developments in gene editing and CRISPR technology. 02 Mar 2018. AddThis Sharing Buttons. Share to LinkedIn LinkedInShare to Facebook FacebookShare to Twitter TwitterShare to Email EmailShare to More … Crispr Therapeutics (CRSP) PT Raised to $51.00 at CitigroupThe Ledger Gazette Analyst Views On Top Movers In Recent Trade: JRjr33, Inc. (JRJR), CRISPR Therapeutics AG (CRSP)Post Analyst What Recent Ownership Trends Suggest About CRISPR Therapeutics AG (CRSP)’s Future PerformanceStockNewsGazette The Lincolnian Online –registrarjournal.com –Kaplan Herald all 12 news articles » |
BioPharma-Reporter.com |
Draper touts new bioprocessing method as ‘next big advance in CAR T-cell treatment’
BioPharma-Reporter.com Viral vectors, the delivery vehicle of genomic materials into specific cells, can account for as much as 75% of a treatment’s cost, according to the company. “Second, the device removes the expense of additional touch labor and reduces the potential … |